These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

281 related items for PubMed ID: 16562643

  • 1. [Changes in serum lipids, plasma fibrinogen and other haemostatic parameters induced by ciprofibrate action in hyperlipidemic patients with and without coronary artery disease].
    Espinosa RA, Rodríguez-Roa E, Nagy E, Mijares ME, Rodríguez-Larralde A, Gil A, Lundberg U, Carvajal Z, Castillo L, Arocha-Piñango CL.
    Invest Clin; 2006 Mar; 47(1):35-48. PubMed ID: 16562643
    [Abstract] [Full Text] [Related]

  • 2. Blood coagulation, fibrinolytic activity and lipid profile in subclinical thyroid disease: subclinical hyperthyroidism increases plasma factor X activity.
    Erem C.
    Clin Endocrinol (Oxf); 2006 Mar; 64(3):323-9. PubMed ID: 16487444
    [Abstract] [Full Text] [Related]

  • 3. Effects of gemfibrozil and ciprofibrate on plasma levels of tissue-type plasminogen activator, plasminogen activator inhibitor-1 and fibrinogen in hyperlipidaemic patients.
    Kockx M, de Maat MP, Knipscheer HC, Kastelein JJ, Kluft C, Princen HM, Kooistra T.
    Thromb Haemost; 1997 Oct; 78(4):1167-72. PubMed ID: 9364979
    [Abstract] [Full Text] [Related]

  • 4. Prothrombotic and lipoprotein variables in patients attending a cardiovascular risk management clinic: response to ciprofibrate or lifestyle advice.
    Mikhailidis DP, Ganotakis ES, Spyropoulos KA, Jagroop IA, Byrne DJ, Winder AF.
    Int Angiol; 1998 Dec; 17(4):225-33. PubMed ID: 10204653
    [Abstract] [Full Text] [Related]

  • 5. Effect of ciprofibrate on lipoproteins, fibrinogen, renal function, and hepatic enzymes.
    Rizos E, Bairaktari E, Ganotakis E, Tsimihodimos V, Mikhailidis DP, Elisaf M.
    J Cardiovasc Pharmacol Ther; 2002 Oct; 7(4):219-26. PubMed ID: 12490967
    [Abstract] [Full Text] [Related]

  • 6. [Effect of ciprofibrate on the endothelial dysfunction of patients with combined dyslipidemia].
    Kovács I, Tarján J, Császár A.
    Orv Hetil; 2001 Apr 15; 142(15):775-9. PubMed ID: 11367862
    [Abstract] [Full Text] [Related]

  • 7. [Evaluation of efficacy and safety of etofibrate in primary hyperlipidemia. A multicenter study].
    dos Santos JE, Loures-Vale AA, Novazzi JP, Rabelo LM, Martinez TL.
    Arq Bras Cardiol; 1996 Dec 15; 67(6):419-22. PubMed ID: 9246832
    [Abstract] [Full Text] [Related]

  • 8. Ciprofibrate treatment decreases non-high density lipoprotein cholesterol and triglycerides and increases high density lipoprotein cholesterol in patients with Frederickson type IV dyslipidemia phenotype.
    Bermúdez-Pirela V, Souki A, Cano-Ponce C, Bermúdez-Arias F, Mengual-Moreno E, Leal-Gonzalez E, Lemus-Antepaz M, de Bravo MC, de Díaz AA, de Pirela NL, Cano-Peñaloza R, Puche-Medina G, Arraiz N, Reyna-Villazmil N, Contreras F, Israili ZH, Valasco M.
    Am J Ther; 2007 Dec 15; 14(2):213-20. PubMed ID: 17414592
    [Abstract] [Full Text] [Related]

  • 9. Efficacy of ciprofibrate in primary type II and IV hyperlipidemia: the Italian multicenter study.
    Cattin L, Da Col PG, Feruglio FS, Finazzo L, Rimondi S, Descovich G, Manzato E, Zambon S, Crepaldi G, Siepi D.
    Clin Ther; 1990 Dec 15; 12(6):482-8. PubMed ID: 2289217
    [Abstract] [Full Text] [Related]

  • 10. [Lipanor treatment of atherogenic hyperlipoproteinemia].
    Susekov AV, Tvorogova MG, Arabidze GG, Kukharchuk VV.
    Ter Arkh; 1998 Dec 15; 70(9):57-61. PubMed ID: 9821228
    [Abstract] [Full Text] [Related]

  • 11. [Lipid changes of fibrinogen and of platelet aggregation induced by etofibrate].
    Fonseca FA, Novazzi JP, Cendoroglo MS, Duarte M, Almeida Pinto LE, Rabelo LM, da Rocha Martinez TL.
    Arq Bras Cardiol; 1996 Jan 15; 66(1):33-5. PubMed ID: 8731322
    [Abstract] [Full Text] [Related]

  • 12. Etofibrate decreases factor VII and fibrinogen levels in patients with polymetabolic syndrome.
    Jastrzebska M, Torbus-Lisiecka B, Pieczul-Mróz J, Chelstowski K, Kopciewicz J, Naruszewicz M.
    Int J Clin Pharmacol Res; 1999 Jan 15; 19(1):19-25. PubMed ID: 10450539
    [Abstract] [Full Text] [Related]

  • 13. The effect of various menopausal hormone therapies on markers of inflammation, coagulation, fibrinolysis, lipids, and lipoproteins in healthy postmenopausal women.
    Zegura B, Guzic-Salobir B, Sebestjen M, Keber I.
    Menopause; 2006 Jan 15; 13(4):643-50. PubMed ID: 16837886
    [Abstract] [Full Text] [Related]

  • 14. Nicotinic acid treatment shifts the fibrinolytic balance favourably and decreases plasma fibrinogen in hypertriglyceridaemic men.
    Johansson JO, Egberg N, Asplund-Carlson A, Carlson LA.
    J Cardiovasc Risk; 1997 Jun 15; 4(3):165-71. PubMed ID: 9475670
    [Abstract] [Full Text] [Related]

  • 15. Ciprofibrate versus gemfibrozil in the treatment of mixed hyperlipidemias: an open-label, multicenter study.
    Aguilar-Salinas CA, Fanghänel-Salmón G, Meza E, Montes J, Gulías-Herrero A, Sánchez L, Monterrubio-Flores EA, González-Valdez H, Gómez Pérez FJ.
    Metabolism; 2001 Jun 15; 50(6):729-33. PubMed ID: 11398153
    [Abstract] [Full Text] [Related]

  • 16. Decrease in inflammatory cardiovascular risk markers in hyperlipidemic diabetic patients treated with fenofibrate.
    Wu TJ, Ou HY, Chou CW, Hsiao SH, Lin CY, Kao PC.
    Ann Clin Lab Sci; 2007 Jun 15; 37(2):158-66. PubMed ID: 17522372
    [Abstract] [Full Text] [Related]

  • 17. Comparative effects of statin and fibrate on nitric oxide bioactivity and matrix metalloproteinase in hyperlipidemia.
    Koh KK, Ahn JY, Jin DK, Han SH, Kim HS, Choi IS, Ahn TH, Shin EK, Jeong EM.
    Int J Cardiol; 2004 Nov 15; 97(2):239-44. PubMed ID: 15458690
    [Abstract] [Full Text] [Related]

  • 18. [A trial of the use of the hypolipidemic preparation Lipanor (ciprofibrate) in patients with primary hyperlipidemia].
    Kukharchuk VV, Rozhkova TA, Kotova LA, Tvorogova MG, Semenova OA.
    Ter Arkh; 1996 Nov 15; 68(6):58-61. PubMed ID: 8771689
    [Abstract] [Full Text] [Related]

  • 19. The effect of pirozadil on plasma lipids and lipoproteins in 1185 hyperlipidaemic subjects. Multicentre study in general practice in Spain.
    Tapounet R, Marti Ragué I.
    Drugs Exp Clin Res; 1987 Nov 15; 13(7):447-50. PubMed ID: 3652931
    [Abstract] [Full Text] [Related]

  • 20. Inflammatory markers and lipid profile in patients of coronary artery disease.
    Iqbal T, Raza N, Marwat ZI, Riyaz A.
    J Ayub Med Coll Abbottabad; 2011 Nov 15; 23(3):123-6. PubMed ID: 23272452
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.